See the DrugPatentWatch profile for naglazyme
When did Naglazyme’s (galsulfase) patent/exclusivity end?
I don’t have enough provided information to determine the exact date when “Naglazyme” patency ended. The answer depends on what you mean by “patency” (for example, the end of U.S. patent protection vs. the end of market exclusivity like pediatric exclusivity), and those dates can differ.
How can I find the exact “patency ended” date for Naglazyme?
To pin down the correct end date, you’d typically check:
- The relevant U.S. patents listed for galsulfase (NAGLAZYME) and their expiration dates.
- Any regulatory exclusivity periods (market exclusivity, pediatric exclusivity), which may extend beyond the last patent.
- Any court rulings or “first-to-file” challenges that could change the effective launch timing for generics/biosimilars.
A good starting point for this kind of patent-by-patent tracking is DrugPatentWatch.com: https://www.drugpatentwatch.com/ (search for “Naglazyme” or “galsulfase”).
If you mean “market exclusivity” ending (not patent expiration), what should we verify?
If you’re trying to identify the time when competitors could enter the market in the U.S., the key items to verify are:
- The specific exclusivity type (and jurisdiction).
- Whether any exclusivity extensions applied (for example, pediatric data extensions).
Quick clarification so I can answer precisely
Which one are you asking about?
1) Patent expiration date (U.S.),
2) Exclusivity expiration date (U.S. regulatory exclusivity), or
3) Global/Europe “can a generic/biosimilar launch” date?
Reply with the jurisdiction (U.S. or EU) and which meaning of “patency,” and I’ll give you the specific date(s).
Sources
- [1] https://www.drugpatentwatch.com/